Westlake Village Biopartners’ backed Acelyrin makes first acquisition
Acelyrin, a Los Angeles-based biotechnology company, announced its first acquisition of ValenzaBio, a privately held company developing therapies for autoimmune and inflammatory diseases, in an all-stock transaction, the company said Jan. 5. With the acquisition, Acelyrin gains multiple clinical and pre-clinical development programs to its robust immunology pipeline, which is led by izokibep, a small Read More →
Community Memorial Health adds CEO, Chief of Staff
Mick Zdeblick officially stepped into his new role as the CEO of Community Memorial Health on Jan. 9, replacing Gary Wilde, who retired after helming the position since 2004. Community Memorial Health, which offers a network of services throughout Ventura County, welcomes Zdeblick from Medford, Oregon, where he served as the CEO of Asante Rogue Read More →
Health Forecast: ‘Tripledemic’ a real concern to start 2023
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Mercado: Central Coast’s unique technology landscape will continue thrive in 2023
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Travel Forecast: Central Coast to remain desirable spot
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Technology Forecast: Innovation will be the theme for 2023
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Capsida announces multi-year agreement with Eli Lilly subsidiary
Thousand Oaks-based Capsida Therapeutics has entered into a multi-year agreement with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, to develop transformative genetic medicines for serious diseases, Capisda announced Jan. 4. As per the agreement, Capsida will receive $55 million in the form of an upfront payment and a commitment to participate Read More →
